OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chagpar Discusses Benefit of Primary Tumor Surgery in Breast Cancer

May 3rd 2018

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the potential benefit of primary tumor surgery for patients with breast cancer.

Dr. Wolf Discusses High-Risk Multiple Myeloma

May 2nd 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses high-risk multiple myeloma.

Dr. Beatty on the Potential for Immunotherapy in GI Malignancies

May 2nd 2018

Gregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.

Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

May 2nd 2018

Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL

May 2nd 2018

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.

Dr. Welling on SIRT in Patients With Hepatobiliary Neoplasms

May 1st 2018

Theodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.

Dr. Simeone on Emerging Subtypes of Pancreatic Cancer

May 1st 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses emerging subtypes of pancreatic cancer.

Dr. Urbanic on the Role of Radiotherapy in Oligometastatic NSCLC

May 1st 2018

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the role of radiotherapy in oligometastatic non–small cell lung cancer (NSCLC).

Dr. Postow on FDA Approval of Adjuvant Dabrafenib Plus Trametinib in BRAF-Mutant Melanoma

May 1st 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Dr. Weber on the FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF-Mutant Melanoma

May 1st 2018

Jeffrey S. Weber, MD, PhD, the Laura and Isaac Perlmutter Professor of Oncology, co-director of the Melanoma Research Program, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, and a 2016 Giant of Cancer Care® in Melanoma, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Dr. Slamon Discusses the Future of Biosimilars in Oncology

April 30th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the future of biosimilars in oncology.

Dr. Choyke on Advancements in Imaging for Prostate Cancer

April 30th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses advances in imaging for prostate cancer.

Dr. Garon on Immunotherapy Combinations in NSCLC

April 30th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non–small cell lung cancer.

Dr. Usmani on PD-1/PD-L1 Inhibitors in Hematologic Malignancies

April 30th 2018

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the evolution of PD-1/PD-L1 inhibitors in the treatment of patients with hematologic malignancies.

Dr. Soliman on Investigational Combination Therapies in Patients With Breast Cancer

April 30th 2018

Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.

Dr. Hurvitz on the FDA Approval Process for Biosimilars

April 30th 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.

Dr. Ghosh on PET-Adapted Therapy in Patients With Hodgkin Lymphoma

April 28th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses PET-adapted therapy in patients with Hodgkin lymphoma.

Dr. Brufsky on Multiparametric Genomic Assays in Breast Cancer

April 28th 2018

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses multiparametric assays in breast cancer.

Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

April 28th 2018

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

Dr. Leslie Discusses Advancements in Mantle Cell Lymphoma

April 28th 2018

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses advancements in mantle cell lymphoma.